LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Aandelen Lijst・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

3.69 1.93

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.6

Max

3.7800000000000002

Belangrijke statistieken
By Trading Economics
Inkomsten	44M -26M
Verkoop	-5.8M 42M
Winstmarge	-61.388
Werknemers	550
EBITDA	44M -22M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+8.11% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	246M 1.3B
Vorige openingsprijs	1.76
Vorige sluitingsprijs	3.69

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

2.02 / 2.115 Steun & Weerstand

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 dec 2025, 22:13 UTC

Winsten

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dec 2025, 21:40 UTC

Winsten

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dec 2025, 18:51 UTC

Acquisities, Fusies, Overnames

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dec 2025, 16:57 UTC

Belangrijke Marktbewegers

Clear Secure Rises on Medicare Identity Verification Contract

9 dec 2025, 23:46 UTC

Marktinformatie

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dec 2025, 23:46 UTC

Acquisities, Fusies, Overnames

Legend Holdings Stake in Lenovo Now at 32.34%

9 dec 2025, 23:45 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dec 2025, 23:44 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dec 2025, 23:43 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dec 2025, 23:43 UTC

Acquisities, Fusies, Overnames

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dec 2025, 23:35 UTC

Marktinformatie

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dec 2025, 22:42 UTC

Winsten

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dec 2025, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

9 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 dec 2025, 21:48 UTC

Marktinformatie

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dec 2025, 21:36 UTC

Winsten

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dec 2025, 20:28 UTC

Marktinformatie

Oil Futures Decline for Second Straight Session -- Market Talk

9 dec 2025, 20:27 UTC

Acquisities, Fusies, Overnames

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dec 2025, 20:27 UTC

Acquisities, Fusies, Overnames

Teck Reports Voting Results From Special Meeting of Hldrs

9 dec 2025, 20:26 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dec 2025, 20:21 UTC

Marktinformatie

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dec 2025, 19:52 UTC

Winsten

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dec 2025, 19:17 UTC

Winsten

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 dec 2025, 17:11 UTC

Winsten

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

8.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD 8.11%

Hoogste 4 USD

Laagste 4 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Maravai LifeSciences Holdings Inc (Class A) - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.